

1. Company details

Name of entity:	Biome Australia Limited
ABN:	51 627 364 014
Reporting period:	For the half-year ended 31 December 2022
Previous period:	For the half-year ended 31 December 2021

2. Results for announcement to the market

			\$
Revenues from ordinary activities	up	87.5% to	3,380,746
Loss from ordinary activities after tax attributable to the owners of Biome Australia Limited	down	29.9% to	(1,738,930)
Loss for the half-year attributable to the owners of Biome Australia Limited	down	29.9% to	(1,738,930)

Dividends

There were no dividends paid, recommended or declared during the current financial period.

Comments

The loss for the consolidated entity after providing for income tax amounted to \$1,738,930 (31 December 2021: \$2,479,914).

Financial Performance

During the half year period, the Company experienced strong sales growth with revenue increasing by 87.5% to \$3,380,746 compared to the previous corresponding period (1H22 \$1,802,611). The sales growth has been driven primarily by Biome’s Activated Probiotics, live biotherapeutics (probiotics). The Activated Probiotics range accounts for over 96% of sales for the period. Company (quarterly) sales continue its strong growth momentum as depicted in Figure 1 below.




Fig. 1. Biome Quarterly Sales (Sep Qtr 20 to Dec Qtr 22)

Gross margin on sales for the half year period improved to 59% compared to 57.7% (1H22) in the previous corresponding period.

The loss for the consolidated entity after providing for income tax amounted to \$1,738,930 (31 December 2021: \$2,479,914). Sales and marketing costs increased by \$540,833 to \$2,420,501 as a result of increased expenditure on promoting the Company's products. Despite this increase in sales and marketing costs, total operating expenses remained unchanged at \$3.78 million.

Retail pharmacy partner Terry White Chemmart and pharmacy wholesaler Symbion have both reported that Biome's Activated Probiotics has remained the number one growth brand in their professional vitamin categories over the 12 months to December 2022.

The sales trajectory has also benefited from the Company achieving scale in distribution. The onboarding of Priceline Pharmacy stores at the end of August 2022 took the Company's distribution footprint to over 3,000 distribution points across both pharmacy and independent health practitioner channels. Priceline Pharmacy also reported Biome's Activated Probiotics was their number one growth brand as of 31 December 2022. Biome's largest distribution channel continues to be community pharmacy. The pharmacy channel reported same store sales growth of 59% for the half year period to December 2022 compared to the previous corresponding period.

With the mid-2021 launch into the health food and practitioner channels, securing distribution with Osborne Health, Rener Health, Ariya and vital.ly has supported consistent growth in this new channel with over 150% channel growth year-on-year. The independent health practitioner channel in Australia and overseas now represents more than 33% of Biome's total sales revenue.

New product development has been a key focus in 1H23. The result has led to three new product launches planned for 2H23 and more to follow in FY24. Biome will launch Biome Dental Probiotic, Biome Lax Probiotic and Biome Recovery Probiotic into the Activated Probiotics brand. All new products planned for launch in FY23 have passed Biome's rigorous criteria for new product development; they have human clinical data supporting their efficacy, have little or no direct competition, aim to improve the quality of life of the patients who take them and support maintaining our average gross margin.

Biome launched its new investor hub in December in partnership with Fresh Amplify. The hub allows shareholders to access Company ASX announcements, view webinars and engage directly with the Company. Biome is planning an investor webinar for March and a broker roadshow in early Q423.

Financial Position

The Company has \$3,734,952 in cash as at 31 December 2022. At 31 December 2022, the Company has net current assets of \$4,295,940 and net assets of \$4,772,273. The Company incurred a cash outflow from operations in the half year of \$1,408,439.

3. Net tangible assets

	Reporting period Cents	Previous period Cents
Net tangible assets per ordinary security	<u>2.41</u>	<u>3.28</u>

4. Control gained over entities

Not applicable.

5. Loss of control over entities

Not applicable.

6. Dividends

Current period

There were no dividends paid, recommended or declared during the current financial period.

Previous period

There were no dividends paid, recommended or declared during the previous financial period.

7. Dividend reinvestment plans

Not applicable.

8. Details of associates and joint venture entities

Not applicable.

9. Foreign entities

Details of origin of accounting standards used in compiling the report:

Not applicable.

10. Audit qualification or review

Details of audit/review dispute or qualification (if any):

The financial statements were subject to a review by the auditors and the review report is attached as part of the Interim Report.

11. Attachments

Details of attachments (if any):

The Interim Report of Biome Australia Limited for the half-year ended 31 December 2022 is attached.

12. Signed

Signed  _____

Mr Ilario Faenza
Chairman

Date: 27 February 2023

Biome Australia Limited

ABN 51 627 364 014

Interim Report - 31 December 2022

Directors	Blair William Brabin Vega Norfolk (Managing Director) Ilario Thomas Faenza (Non-Executive Director) Dominique Gayle Fisher AM (Independent Non-Executive Director)
Company secretary	George Lazarou
Chief financial officer	Douglas Chee Yong Loh
Registered office	192-194 Johnston Street Collingwood Victoria 3066 Phone: +61 3 9017 5800
Principal place of business	192-194 Johnston Street Collingwood Victoria 3066
Share register	Automatic Pty Ltd 477 Collins Street Melbourne Victoria 3000 Phone: 1300 288 664
Auditor	JTP Assurance Level 10, 446 Collins Street Melbourne VIC 3000
Stock exchange listing	Biome Australia Limited shares are listed on the Australian Securities Exchange (ASX code: BIO)
Website	www.biomeaustralia.com

Biome Australia Limited
Contents
31 December 2022



Directors' report	3
Auditor's independence declaration	5
Statement of profit or loss and other comprehensive income	6
Statement of financial position	7
Statement of changes in equity	8
Statement of cash flows	9
Notes to the financial statements	10
Directors' declaration	14
Independent auditor's review report to the members of Biome Australia Limited	15

The directors present their report, together with the financial statements, on the consolidated entity (referred to hereafter as the 'consolidated entity') consisting of Biome Australia Limited (referred to hereafter as the 'company' or 'parent entity') and the entities it controlled at the end of, or during, the half-year ended 31 December 2022.

Directors

The following persons were directors of Biome Australia Limited during the whole of the financial half-year and up to the date of this report, unless otherwise stated:

- Mr Ilario Thomas Faenza - Non-executive Director
- Mr Blair William Brabin Vega Norfolk - Managing Director
- Ms Dominique Gayle Fisher AM - Independent Non-executive Director

Principal activities

The principal continuing activities of the Group during the financial half-year were developing, manufacturing and distributing innovative evidence-based products linking the gut and human health through the Group owned brands:

- Activated Nutrients, a range of completely organic, plant-based, all-in-one nutritional products;
- Activated Probiotics, a first-of-its-kind range of clinically-backed precision probiotics; and
- AXP, a certified range of performance products for athletes.

Review of operations

Financial Performance

During the half year period, the Company experienced strong sales growth with revenue increasing by 87.5% to \$3,380,746 compared to the previous corresponding period (1H22 \$1,802,611). The sales growth has been driven primarily by Biome's Activated Probiotics, live biotherapeutics (probiotics). The Activated Probiotics range accounts for over 96% of sales for the period. Company (quarterly) sales continue its strong growth momentum as depicted in Figure 1 below.




Fig. 1. Biome Quarterly Sales (Sep Qtr 20 to Dec Qtr 22)

Gross margin on sales for the half year period improved to 59% compared to 57.7% (1H22) in the previous corresponding period.

The loss for the consolidated entity after providing for income tax amounted to \$1,738,930 (31 December 2021: \$2,479,914). Sales and marketing costs increased by \$540,833 to \$2,420,501 as a result of increased expenditure on promoting the Company's products. Despite this increase in sales and marketing costs, total operating expenses remained unchanged at \$3.78 million.

Retail pharmacy partner Terry White Chemmart and pharmacy wholesaler Symbion have both reported that Biome's Activated Probiotics has remained the number one growth brand in their professional vitamin categories over the 12 months to December 2022.

The sales trajectory has also benefited from the Company achieving scale in distribution. The onboarding of Priceline Pharmacy stores at the end of August 2022 took the Company's distribution footprint to over 3,000 distribution points across both pharmacy and independent health practitioner channels. Priceline Pharmacy also reported Biome's Activated Probiotics was their number one growth brand as of 31 December 2022. Biome's largest distribution channel continues to be community pharmacy. The pharmacy channel reported same store sales growth of 59% for the half year period to December 2022 compared to the previous corresponding period.

With the mid-2021 launch into the health food and practitioner channels, securing distribution with Osborne Health, Rener Health, Ariya and vital.ly has supported consistent growth in this new channel with over 150% channel growth year-on-year. The independent health practitioner channel in Australia and overseas now represents more than 33% of Biome's total sales revenue.

New product development has been a key focus in 1H23. The result has led to three new product launches planned for 2H23 and more to follow in FY24. Biome will launch Biome Dental Probiotic, Biome Lax Probiotic and Biome Recovery Probiotic into the Activated Probiotics brand. All new products planned for launch in FY23 have passed Biome's rigorous criteria for new product development; they have human clinical data supporting their efficacy, have little or no direct competition, aim to improve the quality of life of the patients who take them and support maintaining our average gross margin.

Biome launched its new investor hub in December in partnership with Fresh Amplify. The hub allows shareholders to access Company ASX announcements, view webinars and engage directly with the Company. Biome is planning an investor webinar for March and a broker roadshow in early Q423.

Financial Position

The Company has \$3,734,952 in cash as at 31 December 2022. At 31 December 2022, the Company has net current assets of \$4,295,940 and net assets of \$4,772,273. The Company incurred a cash outflow from operations in the half year of \$1,408,439.

Significant changes in the state of affairs

There were no significant changes in the state of affairs of the consolidated entity during the financial half-year.

Auditor's independence declaration

A copy of the auditor's independence declaration as required under section 307C of the Corporations Act 2001 is set out immediately after this directors' report.

This report is made in accordance with a resolution of directors, pursuant to section 306(3)(a) of the Corporations Act 2001.

On behalf of the directors



Mr Ilario Faenza
Chairman

27 February 2023

**AUDITOR'S INDEPENDENCE DECLARATION
UNDER SECTION 307C OF THE CORPORATIONS ACT 2001
TO THE DIRECTORS OF BIOME AUSTRALIA LIMITED**

I declare that, to the best of my knowledge and belief, during the half-year ended 31 December 2022 there have been:

- (i) no contraventions of the auditor independence requirements as set out in the *Corporations Act 2001* in relation to the review; and
- (ii) No contraventions of any applicable code of professional conduct in relation to the review.

JTP Assurance

JTP ASSURANCE
Chartered Accountants

W. Tarrant

WAYNE TARRANT
Partner

Signed at Melbourne this 27th day of February 2023

Biome Australia Limited
Statement of profit or loss and other comprehensive income
For the half-year ended 31 December 2022



		Consolidated	
	Note	31 December 2022	31 December 2021
		\$	\$
Revenue			
Sales revenue	5	3,380,746	1,802,611
Cost of goods sold		<u>(1,387,335)</u>	<u>(762,087)</u>
Gross profit		<u>1,993,411</u>	<u>1,040,524</u>
Other income	6	43,832	256,626
Expenses			
Sales and marketing expenses		(2,420,501)	(1,879,668)
Corporate and administrative expenses		(1,000,547)	(1,496,456)
Occupancy costs		(46,191)	(57,159)
Finance expenses		(14,899)	(26,642)
Depreciation and amortisation expense		(99,382)	(21,370)
Other expenses		<u>(194,653)</u>	<u>(295,769)</u>
Loss before income tax expense		(1,738,930)	(2,479,914)
Income tax expense		<u>-</u>	<u>-</u>
Loss after income tax expense for the half-year attributable to the owners of Biome Australia Limited		(1,738,930)	(2,479,914)
Other comprehensive income for the half-year, net of tax		<u>-</u>	<u>-</u>
Total comprehensive income for the half-year attributable to the owners of Biome Australia Limited		<u><u>(1,738,930)</u></u>	<u><u>(2,479,914)</u></u>
		Cents	Cents
Basic earnings per share	13	(0.87)	(1.61)
Diluted earnings per share	13	(0.87)	(1.61)

The above statement of profit or loss and other comprehensive income should be read in conjunction with the accompanying notes

Biome Australia Limited
Statement of financial position
As at 31 December 2022



	Consolidated	
	31 December	30 June 2022
Note	2022	2022
	\$	\$
Assets		
Current assets		
Cash and cash equivalents	3,734,952	5,493,394
Trade and other receivables	1,109,776	794,148
Inventories	2,030,999	1,300,075
Other assets	66,306	55,939
Total current assets	<u>6,942,033</u>	<u>7,643,556</u>
Non-current assets		
Property, plant and equipment	469,965	174,695
Right-of-use assets	383,981	433,000
Total non-current assets	<u>853,946</u>	<u>607,695</u>
Total assets	<u>7,795,979</u>	<u>8,251,251</u>
Liabilities		
Current liabilities		
Trade and other payables	2,269,059	1,125,558
Lease liabilities	95,575	91,700
Employee benefits	281,459	133,598
Total current liabilities	<u>2,646,093</u>	<u>1,350,856</u>
Non-current liabilities		
Lease liabilities	326,855	375,348
Employee benefits	50,758	-
Total non-current liabilities	<u>377,613</u>	<u>375,348</u>
Total liabilities	<u>3,023,706</u>	<u>1,726,204</u>
Net assets	<u>4,772,273</u>	<u>6,525,047</u>
Equity		
Issued capital	20,625,991	20,639,835
Share options reserve	415,442	415,442
Accumulated losses	(16,269,160)	(14,530,230)
Total equity	<u>4,772,273</u>	<u>6,525,047</u>

The above statement of financial position should be read in conjunction with the accompanying notes

Biome Australia Limited
Statement of changes in equity
For the half-year ended 31 December 2022



Consolidated	Ordinary shares \$	Option reserve \$	Performance rights \$	Accumulated losses \$	Total equity \$
Balance at 1 July 2021	9,830,488	83,205	1,559,970	(9,893,535)	1,580,128
Loss after income tax expense for the half-year	-	-	-	(2,479,914)	(2,479,914)
Other comprehensive income for the half-year, net of tax	-	-	-	-	-
Total comprehensive income for the half-year	-	-	-	(2,479,914)	(2,479,914)
<i>Transactions with owners in their capacity as owners:</i>					
Contributions of equity, net of transaction costs	8,508,210	-	-	-	8,508,210
Share-based payments	-	405,734	-	-	405,734
Exercise of performance rights	2,301,137	-	(2,301,137)	-	-
Issue of performance rights	-	-	585,615	-	585,615
Cancellation of options	-	(14,060)	-	-	(14,060)
Transfer to accumulated losses	-	-	155,552	(155,552)	-
Balance at 31 December 2021	<u>20,639,835</u>	<u>474,879</u>	<u>-</u>	<u>(12,529,001)</u>	<u>8,585,713</u>
Consolidated	Ordinary shares \$	Option reserve \$	Accumulated losses \$	Total equity \$	
Balance at 1 July 2022	20,639,835	415,442	(14,530,230)	6,525,047	
Loss after income tax expense for the half-year	-	-	(1,738,930)	(1,738,930)	
Other comprehensive income for the half-year, net of tax	-	-	-	-	
Total comprehensive income for the half-year	-	-	(1,738,930)	(1,738,930)	
<i>Transactions with owners in their capacity as owners:</i>					
Cost of capital raising (note 9)	(13,844)	-	-	(13,844)	
Balance at 31 December 2022	<u>20,625,991</u>	<u>415,442</u>	<u>(16,269,160)</u>	<u>4,772,273</u>	

The above statement of changes in equity should be read in conjunction with the accompanying notes

Biome Australia Limited
Statement of cash flows
For the half-year ended 31 December 2022



	Consolidated	
	31 December	31 December
Note	2022	2021
	\$	\$
Cash flows from operating activities		
Receipts from customers (inclusive of GST)	3,054,168	1,998,471
Payments to suppliers and employees (inclusive of GST)	(4,495,783)	(3,962,803)
R&D tax refund	-	223,275
Other government grants received	36,600	33,000
Interest received	7,232	351
Interest paid on operating leases	(10,656)	-
	<u>(1,408,439)</u>	<u>(1,707,706)</u>
Net cash used in operating activities		
Cash flows from investing activities		
Payments for leasehold improvements	(260,556)	-
Proceeds from disposal of property, plant and equipment	-	24,519
	<u>(260,556)</u>	<u>24,519</u>
Net cash from/(used in) investing activities		
Cash flows from financing activities		
Proceeds from issue of shares	9	9,678,651
Payments for lease liabilities	(44,619)	-
Share issue transaction costs	-	(764,707)
Repayment of borrowings	-	(96,767)
	<u>(44,619)</u>	<u>8,817,177</u>
Net cash from/(used in) financing activities		
Net increase/(decrease) in cash and cash equivalents	(1,713,614)	7,133,990
Cash and cash equivalents at the beginning of the financial half-year	5,493,394	609,978
Effects of exchange rate changes on cash and cash equivalents	(44,828)	-
	<u>3,734,952</u>	<u>7,743,968</u>
Cash and cash equivalents at the end of the financial half-year		

The above statement of cash flows should be read in conjunction with the accompanying notes

Note 1. General information

The financial statements cover Biome Australia Limited as a consolidated entity consisting of Biome Australia Limited and the entities it controlled at the end of, or during, the half-year. The financial statements are presented in Australian dollars, which is Biome Australia Limited's functional and presentation currency.

Biome Australia Limited is a listed public company limited by shares, incorporated and domiciled in Australia. Its registered office and principal place of business are:

Registered office

192-194 Johnston Street
Collingwood Victoria 3066

Principal place of business

192-194 Johnston Street
Collingwood Victoria 3066

A description of the nature of the consolidated entity's operations and its principal activities are included in the directors' report, which is not part of the financial statements.

The financial statements were authorised for issue, in accordance with a resolution of directors, on 27 February 2023.

Note 2. Significant accounting policies

These general purpose financial statements for the interim half-year reporting period ended 31 December 2022 have been prepared in accordance with Australian Accounting Standard AASB 134 'Interim Financial Reporting' and the Corporations Act 2001, as appropriate for for-profit oriented entities. Compliance with AASB 134 ensures compliance with International Financial Reporting Standard IAS 34 'Interim Financial Reporting'.

These general purpose financial statements do not include all the notes of the type normally included in annual financial statements. Accordingly, these financial statements are to be read in conjunction with the annual report for the year ended 30 June 2022 and any public announcements made by the company during the interim reporting period in accordance with the continuous disclosure requirements of the Corporations Act 2001.

The principal accounting policies adopted are consistent with those of the previous financial year and corresponding interim reporting period, unless otherwise stated.

New or amended Accounting Standards and Interpretations adopted

The consolidated entity has adopted all of the new or amended Accounting Standards and Interpretations issued by the Australian Accounting Standards Board ('AASB') that are mandatory for the current reporting period.

Any new or amended Accounting Standards or Interpretations that are not yet mandatory have not been early adopted.

Note 3. Critical accounting judgements, estimates and assumptions

The preparation of the financial statements requires management to make judgements, estimates and assumptions that affect the reported amounts in the financial statements. Management continually evaluates its judgements and estimates in relation to assets, liabilities, contingent liabilities, revenue and expenses. Management bases its judgements, estimates and assumptions on historical experience and on other various factors, including expectations of future events, management believes to be reasonable under the circumstances. The resulting accounting judgements and estimates will seldom equal the related actual results. The judgements, estimates and assumptions that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities (refer to the respective notes) within the next financial year are discussed below.

Share-based payment transactions

The consolidated entity measures the cost of equity-settled transactions with employees by reference to the fair value of the equity instruments at the date at which they are granted. The fair value is determined by using either the Binomial or Black-Scholes model taking into account the terms and conditions upon which the instruments were granted. The accounting estimates and assumptions relating to equity-settled share-based payments would have no impact on the carrying amounts of assets and liabilities within the next annual reporting period but may impact profit or loss and equity.

Note 3. Critical accounting judgements, estimates and assumptions (continued)

Allowance for expected credit losses

The allowance for expected credit losses assessment requires a degree of estimation and judgement. It is based on the lifetime expected credit loss, grouped based on days overdue, and makes assumptions to allocate an overall expected credit loss rate for each group. These assumptions include recent sales experience and historical collection rates.

Provision for impairment of inventories

The provision for impairment of inventories assessment requires a degree of estimation and judgement. The level of the provision is assessed by taking into account the recent sales experience, the ageing of inventories and other factors that affect inventory obsolescence.

Note 4. Operating segments

Identification of reportable operating segments

The company is organised into one operating segments: researching, developing, manufacturing and distributing innovative evidence-based products linking the gut and human health. This operating segment is based on the internal reports that are reviewed and used by the Board of Directors (who are identified as the Chief Operating Decision Makers ('CODM')) in assessing performance and in determining the allocation of resources. There is no aggregation of operating segments.

Note 5. Sales revenue

	Consolidated	
	31 December 2022	31 December 2021
	\$	\$
Sales - Domestic	3,205,510	1,667,901
Sales - International	175,236	134,710
	<u>3,380,746</u>	<u>1,802,611</u>

Note 6. Other income

	Consolidated	
	31 December 2022	31 December 2021
	\$	\$
Government grants	36,600	33,000
Interest	7,232	351
R & D rebate	-	223,275
Other income	<u>43,832</u>	<u>256,626</u>

Note 7. Current assets - inventories

	Consolidated	
	31 December 2022	30 June 2022
	\$	\$
Raw materials - at cost	43,690	-
Finished goods - at cost	2,113,872	1,555,941
Provision for slow moving and obsolete stock (and samples: June 2022)	(126,563)	(255,866)
	<u>1,987,309</u>	<u>1,300,075</u>
	<u>2,030,999</u>	<u>1,300,075</u>

Note 8. Non-current assets - right-of-use assets

	Consolidated	
	31 December	30 June 2022
	2022	2022
	\$	\$
Land and buildings - right-of-use	490,189	490,189
Less: Accumulated depreciation	(106,208)	(57,189)
	<u>383,981</u>	<u>433,000</u>

Note 9. Equity - issued capital

	Consolidated			
	31 December	30 June 2022	31 December	30 June 2022
	2022	2022	2022	2022
	Shares	Shares	\$	\$
Ordinary shares - fully paid	<u>199,909,857</u>	<u>199,909,857</u>	<u>20,625,991</u>	<u>20,639,835</u>

Movements in ordinary share capital

Details	Date	Shares	Issue price	\$
Balance	1 July 2022	199,909,857		20,639,835
Capital raising costs		-	\$0.00	(13,844)
Balance	31 December 2022	<u>199,909,857</u>		<u>20,625,991</u>

Ordinary shares

Ordinary shares entitle the holder to participate in dividends and the proceeds on the winding up of the company in proportion to the number of and amounts paid on the shares held. The fully paid ordinary shares have no par value and the company does not have a limited amount of authorised capital.

On a show of hands every member present at a meeting in person or by proxy shall have one vote and upon a poll each share shall have one vote.

Share buy-back

There is no current on-market share buy-back.

Note 10. Equity - dividends

There were no dividends paid, recommended or declared during the current or previous financial half-year.

Note 11. Contingent liabilities

Included in the prospectus dated 19 October 2021 the Managing Director is entitled to a long term incentive (LTI) should specified consolidated revenue targets be delivered over a three year period. The maximum liability under this plan is \$1,000,000 to be earned over a three-year period up to and including the year ending 30 June 2024.

The Company intends to start accruing this liability in its accounts once the minimum 80% LTI target of \$16.8m cumulative sales is met prior to 30 June 2024.

The group has no other known contingent liabilities as at 31 December 2022.

Note 12. Events after the reporting period

On 18 January 2023, the Company issued 1,902,689 fully paid ordinary shares under the Company's Employee Incentive Plan for nil cash consideration. The value of the fully paid ordinary shares issued is \$137,564.

No other matter or circumstance has arisen since 31 December 2022 that has significantly affected, or may significantly affect the consolidated entity's operations, the results of those operations, or the consolidated entity's state of affairs in future financial years.

Note 13. Earnings per share

	Consolidated	
	31 December 2022	31 December 2021
	\$	\$
Loss after income tax attributable to the owners of Biome Australia Limited	<u>(1,738,930)</u>	<u>(2,479,914)</u>
	Number	Number
Weighted average number of ordinary shares used in calculating basic earnings per share	<u>199,909,857</u>	<u>153,836,005</u>
Weighted average number of ordinary shares used in calculating diluted earnings per share	<u>199,909,857</u>	<u>153,836,005</u>
	Cents	Cents
Basic earnings per share	(0.87)	(1.61)
Diluted earnings per share	(0.87)	(1.61)

Biome Australia Limited
Directors' declaration
31 December 2022



In the directors' opinion:

- the attached financial statements and notes comply with the Corporations Act 2001, Australian Accounting Standard AASB 134 'Interim Financial Reporting', the Corporations Regulations 2001 and other mandatory professional reporting requirements;
- the attached financial statements and notes give a true and fair view of the consolidated entity's financial position as at 31 December 2022 and of its performance for the financial half-year ended on that date; and
- there are reasonable grounds to believe that the company will be able to pay its debts as and when they become due and payable.

Signed in accordance with a resolution of directors made pursuant to section 303(5)(a) of the Corporations Act 2001.

On behalf of the directors

A handwritten signature in black ink, appearing to read "I. Faenza", written over a horizontal line.

Mr Ilario Faenza
Chairman

27 February 2023

**INDEPENDENT AUDITOR'S REVIEW REPORT TO THE MEMBERS OF BIOME AUSTRALIA LIMITED
ABN 51 627 364 014****Report on the Half-year Financial Report**

We have reviewed the accompanying half-year financial report of Biome Australia Limited, which comprises the consolidated condensed statement of financial position as at 31 December 2022, the consolidated condensed statement of profit or loss, the consolidated condensed statement of comprehensive income, the consolidated condensed statement of changes in equity and the consolidated condensed statement of cash flows for the half-year ended on that date, notes comprising a summary of significant accounting policies and other explanatory information, and the directors' declaration.

Directors' Responsibility for the Half-year Financial Report

The directors of Biome Australia Limited are responsible for the preparation of the half-year financial report that gives a true and fair view in accordance with Australian Accounting Standards (including Australian Accounting Interpretations) and the Corporations Act 2001 and for such internal control as the directors determine is necessary to enable the preparation of the half-year financial report that gives a true and fair view and is free from material misstatement, whether due to fraud or error.

Auditor's Responsibility

Our responsibility is to express a conclusion on the half-year financial report based on our review. We conducted our review in accordance with Auditing Standard on Review Engagements ASRE 2410: Review of a Financial Report Performed by the Independent Auditor of the Entity, in order to state whether, on the basis of the procedures described, we have become aware of any matter that makes us believe that the half-year financial report is not in accordance with the Corporations Act 2001 including: giving a true and fair view of Biome Australia Limited's financial position as at 31 December 2022 and its performance for the half-year ended on that date; and complying with Accounting Standard AASB 134: Interim Financial Reporting and the Corporations Regulations 2001. As the auditor of Biome Australia Limited, ASRE 2410 requires that we comply with the ethical requirements relevant to the audit of the annual financial report.

A review of a half-year financial report consists of making enquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Australian Auditing Standards and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Independence

In conducting our review, we have complied with the independence requirements of the Corporations Act 2001.

Conclusion

Based on our review, which is not an audit, we have not become aware of any matter that makes us believe that the half-year financial report of Biome Australia Limited is not in accordance with the Corporations Act 2001, including:

- (i) giving a true and fair view of Biome Australia Limited 's financial position as at 31 December 2022 and of its performance for the half-year ended on that date; and
- (ii) complying with Accounting Standard AASB 134: Interim Financial Reporting and the Corporations Regulations 2001.

JTP Assurance
JTP ASSURANCE
Chartered Accountants

W. Tarrant
WAYNE TARRANT
Partner

Signed at Melbourne this 27th day of February 2023